

RESEARCH PAPER



Bifidobacterium animalis subspecies lactis modulates the local immune response and glucose uptake in the small intestine of juvenile pigs infected with the parasitic nematode *Ascaris suum*

Gloria Solano-Aguilar^a, Terez Shea-Donohue^b, Kathleen B. Madden^c, Alejandro Quinoñes^d, Ethiopia Beshah^a, Sukla Lakshman^a, Yue Xie^e, Harry Dawson^a, and Joseph F. Urban^a

^aUnited States Department of Agriculture, Agricultural Research Service, Beltsville Human Nutrition Research Center, Diet Genomics and Immunology Laboratory, Beltsville, MD; ^bDepartment of Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD; ^cDepartment of Pediatrics, Uniformed Services University of the Health Sciences, Bethesda, MD; ^dUniversity of California, Riverside Campus, CA; ^eDepartment of Parasitology, Sichuan Agricultural University, College of Veterinary Medicine, Sichuan, China

ABSTRACT

An evaluation of a localized intestinal allergic type-2 response concomitant with consumption of probiotic bacteria is not well documented. This study investigated the effect of feeding probiotic *Bifidobacterium animalis subspecies lactis* (*Bb12*) or a placebo in weaned pigs that were also inoculated with *Ascaris suum* (*A. suum*) eggs to induce a strong Th2-dependent allergic type 2 immune response. Sections of jejunal mucosa were mounted in Ussing chambers to determine changes in permeability and glucose absorption, intestine and liver samples were collected for analysis of type-2 related gene expression, jejunum examined histologically, and sera and intestinal fluid were assayed for parasite antigen specific antibody. The prototypical parasite-induced secretory response to histamine and reduced absorption of glucose in the jejunum were attenuated by feeding *Bb12* without a change in mucosal resistance. Parasite antigen-specific IgA response in the serum and IgG1 and IgG2 response in the ileal fluid were significantly increased in *A. suum*-infected pigs treated with *Bb12* compared to infected pigs given the placebo. *Ascaris suum*-induced eosinophilia in the small intestinal mucosa was inhibited by *Bb12* treatment without affecting the normal expulsion of *A. suum* 4th stage larvae (L4) or the morphometry of the intestine. Expression of genes associated with Th1/Th2 cells, Treg cells, mast cells, and physiological function in the intestine were modulated in *A. suum* infected-pigs treated with *Bb12*. These results suggested that *Bb12* can alter local immune responses and improve intestinal function during a nematode infection by reducing components of a strong allergic type-2 response in the pig without compromising normal parasite expulsion.

ARTICLE HISTORY

Received 2 October 2017
Revised 18 March 2018
Accepted 26 March 2018

KEYWORDS

Probiotic; Th2 cytokines; nematode infection; immune modulation; intestinal function; eosinophil infiltration

Introduction

Two major functions of the intestinal epithelium are to provide a selective barrier to luminal contents and to transport water, nutrients, and electrolytes.^{1–3} The intestinal epithelium is also the interface between luminal contents and the mucosal immune system. It functions not only to reduce responses to food antigens and commensal bacteria, but to activate host defenses against pathogens.⁴ Alterations in epithelial barrier function, therefore, can play a significant role in regulating gastrointestinal disease.⁵

Infection with gastrointestinal parasites affects the physiological and immunological responses of the host. Helminth infection induces a hyper-contractility of

intestinal smooth muscle, inhibition of intestinal glucose absorption, and changes in intestinal secretion that are IL-4 receptor-dependent and STAT6-inducible.⁶ There is growing interest in the use of probiotics to ameliorate the negative effects of infection and allergic disease.⁷ Probiotics have been used to treat a variety of gastrointestinal (GI) ailments including inflammatory bowel disease (IBD), irritable bowel syndrome, viral enteritis, and antibiotic-associated diarrhea.^{8–11} Although little is known definitively about their mechanism of action, probiotics seem to have protective and anti-inflammatory effects on the intestinal mucosa. Proposed mechanisms include the production of ammonia, hydrogen peroxide, and bacteriocins that inhibit the growth of pathogenic bacteria,

CONTACT Gloria Solano-Aguilar ✉ Gloria.SolanoAguilar@ars.usda.gov 10300 Baltimore Avenue, BARC-East, Bldg 307C, Room 225, Beltsville, MD 20705, USA.

© 2018 The Author(s). Published by Taylor & Francis

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (<http://creativecommons.org/licenses/by-nc-nd/4.0/>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.

competition for bacterial adhesion sites on intestinal epithelia, alterations of composition and function of the gut microbiome, and an adjuvant-type stimulation of the immune system against pathogenic organisms.¹²⁻¹⁶ In the present study, we investigated the effect of *Bifidobacterium animalis subspecies lactis* (strain Bb12), a human-derived probiotic used extensively in dairy products,^{17,18} on immune activation and intestinal function of young pigs exposed to migrating *A. suum* larvae.¹⁹ Our results showed that Bb12 modulated the liver and intestinal immune response and intestinal physiology without compromising the normal expulsion of the worms. The parasite-induced reduction in intestinal glucose absorption was ameliorated, the tissue eosinophilic response was reduced, and serum and intestinal antibody responses to the worm were enhanced by feeding Bb12.

Results

Quantitative detection of *Bifidobacterium animalis subspecies lactis* (Bb12) in the intestine

Bb12-treated pigs born to Bb12-treated sows (T/T) had significantly higher copies per gram (cpg) of the *Bifidobacterium animalis subspecies lactis tuf* gene²⁰ in proximal colon contents of *Ascaris suum* (*A. suum*)-infected T/T ($1.8 \pm 0.9 \times 10^5$ cpg) compared to non-

infected control placebo-treated pigs born to placebo-treated sows (C/C) ($0.07 \pm 0.07 \times 10^4$ cpg; $p < 0.05$) or *A. suum*-infected C/C ($0.006 \pm 0.004 \times 10^4$ cpg; $p < 0.05$) with no difference when compared to non-infected T/T pigs ($1.2 \pm 0.9 \times 10^5$ cpg) (Figure 1A).

In the second experiment, T/T pigs had higher cpg in fecal samples collected before *A. suum* infection at six weeks of age ($0.5 \pm 0.1 \times 10^6$ versus $0.2 \pm 0.01 \times 10^6$ cpg; $p < 0.05$) and at 17 days post-inoculation with *A. suum* eggs at nine weeks of age ($2.1 \pm 0.5 \times 10^6$ versus $0.2 \pm 0.01 \times 10^6$ cpg; $p < 0.05$) with a non significant change in cpg when weaned at 3 week of age ($2.56 \pm 1.5 \times 10^6$ cpg vs $0.2 \pm 0.01 \times 10^6$ cpg) (Figure 1B).

In the second study, there was also an increase in *Bifidobacterium animalis subspecies lactis tuf* gene cpg in the proximal colon contents of *A. suum* infected Bb12-treated pigs (T/T) (7.3×10^5 cpg) compared to *A. suum*-infected placebo-treated pigs (C/C) ($1.4 \pm 0.1 \times 10^5$ cpg) ($p < 0.05$) at the time of necropsy (Figure 1C).

Parasite recovery

Ascaris suum L4 are resident in the proximal small intestine at 10 days post-inoculation (p.i.), and are normally expelled distally from day 17 through day 21




Figure 1. Abundance of *Bifidobacterium lactis* in feces and proximal colon contents. Bacterial abundance was determined by detection of the *Bifidobacterium animalis subspecies lactis* species-specific *tuf*-gene by real-time PCR. Data is expressed as mean \pm SEM ($n = 6-8$ per treatment) of *tuf* gene copies per gram (cpg) in feces or intestinal contents. Proximal colon samples from first experiment were collected 21 days p.i. at 2.5 months of age (A). Fecal samples from a second experiment were collected at weaning (3 weeks), pre-infection (6 weeks) and 3 weeks post-inoculation with *Ascaris suum* (9 weeks) (B). Proximal colon contents from the second experiment were collected at 9 weeks (C). Different letters denote differences among treatments after ANOVA ($p < 0.05$).




Figure 2. Detection of *Ascaris suum* fourth-stage larvae (L4). *Ascaris suum* L4 were counted 17 days post inoculation (p.i.) with 2×10^4 infective eggs in the small intestine. Bar represent mean average counts per treatment group from the entire intestine ($n = 7$ per treatment).

p.i., as part of the normal protective response to infection. This pattern was consistent among all *A. suum*-infected pigs regardless of treatment with *Bb12* or placebo. In the first experiment, three of eight pigs from the T/T and three of six pigs from the C/C treatment groups had <30 L4 in the entire small intestine, and the remaining larvae had the predominant larval burden shifted to the distal two sections of the intestine; the




Figure 3. Ussing chamber measurement of intestinal permeability. Segments of muscle-free jejunum mucosa were mounted in Ussing chambers to measure changes in tissue resistance (an index of epithelial permeability) in *A. suum*-infected pigs after continuous treatment with probiotic bacteria *Bb12*. Values are means \pm SE for resistance measures expressed as change in Ω/cm^2 which is inversely correlated to intestinal permeability. Bars represent average resistance values \pm SE ($n = 6$ per treatment group).

total number of L4 were not significantly different between the two groups (data not shown). In the second experiment, there was no significant difference in the number of L4 detected in the entire small intestine of T/T (2875 ± 746) versus C/C (2249 ± 793) treated pigs at 17 days p.i. (Figure 2).

Intestinal function

There was no significant change in resistance in muscle-free mucosa isolated from the jejunum of pigs from any treatment group (Figure 3) in both experiments, which suggested that mucosal resistance was not impaired by parasite infection or feeding *Bb12*. Sections of muscle-free mucosa from the jejunum of pigs infected with *A. suum*, however, showed an increased basal I_{sc} representing the net Cl^- ion flux in response to secretagogues like histamine ($p < 0.05$) (Figure 4A), but not to PGE_2 (Figure 4B). The prototypical *A. suum*-induced prosecretory response to histamine was attenuated significantly ($P < 0.05$) by treatment with *Bb12* (Figure 4A), while the responses to PGE_2 remained unchanged (Figure 4B). Infection with *A. suum* elevated mucosal responses to 5-HT that persisted in pigs fed either placebo or *Bb12* (Figure 4C). Jejunal mucosa from pigs infected with *A. suum* had a characteristic decrease in the absorption of glucose that was attenuated in pigs also fed *Bb12* but not placebo (Figure 5).

Interaction between *Bb12* and *A. suum* at the mRNA level in the jejunum

A selected gene array was evaluated to test the hypothesis that the *Bb12*-modulated genes that regulate a local type-2 response and glucose absorption in the jejunum. Forty-three genes were selected to represent categories of relevant cytokines, cytokine receptors, transcription factors, chemokines, mast cell and goblet cell markers, intestinal tight junction, and physiological markers. The jejunum of pigs treated with *Bb12* showed no significant change in gene expression compared to placebo-treated pigs except for a <2 -fold decrease in expression of *IL4* (Figure 6). Infection with *A. suum* significantly increased ($P < 0.05$) expression of the high affinity Fc receptor of IgE (*FCER1A*), Resistin-like molecule β (*RETNLB*), and increased expression of *IL-9*, *IL-13*, and mast cell tryptase (*TPSAB1*) ($P < 0.1$). There was a significantly decreased expression of eosinophil chemotactic




Figure 4. Mucosal epithelial response to secretagogues. Segments of muscle-free jejunum mucosa were mounted in Ussing chambers to measure concentration-dependent changes in I_{sc} in response to Histamine (A) PGE₂ (B) or 5-hydroxytryptamine 5-HT (C) in pigs infected with *A. suum* after continuous daily feeding with *Bb12*. Values are means \pm SE for repeated experiments, *, $P < 0.05$ vs C/C control pigs; Φ , $P < 0.05$ vs C/C - *A. suum*-infected pigs; λ , $P < 0.05$ vs T/T *Bb12*-treated pigs.

protein *CCL11*, and the inducible gene for cyclooxygenase-2, *Cox-2* (*PTGS2*) ($P < 0.1$) compared to control non-infected pigs (Figure 6). The interaction between *Bb12* treatment and infection with *A. suum* showed a significant ($P < 0.05$) up-regulation in *RETNLB*, *IL-13*, *FCER1A*, *IGHE*, and *IL25* (*IL-17E*). There was a significant ($P < 0.05$) decrease in expression of the signature Th1-associated gene *IFNG*, as well as *IL13RA1*, *IL10*, *MUC5AC*, *TLR9*, *PAR-1* and Treg-derived *SOCS3* (Figure 6). Mast cell-associated markers *CMA1* and *IL3*, and the gene for the tight junction protein, *TJP1*, and *PTGS2*, also were significantly ($P < 0.05$) down-regulated in *A. suum*-infected pigs fed *Bb12* (Figure 6).

Interaction between probiotic and *A. suum* at the mRNA level in the colon, mesenteric lymph nodes (MLN) and liver

Gene expression was measured in the proximal colon mucosa where high numbers of *Bb12* were detected. Significant down-regulation of gene expression in the proximal colon mucosa was only detected for Forkhead box P3 (*FOXP3*) in pigs infected with *A. suum*, and in *RETNLB* and *IL3* in pigs treated with *Bb12* (data not shown). The interaction between infection and *Bb12* significantly decreased ($P < 0.05$) the expression of *TBX21*, *FOXP3*, *CMA*, *IL3*, *SOCS3*, *IL25*, and *TJP1* while only *IGHE* expression was significantly increased (data not shown) Changes in gene




Figure 5. Mucosal epithelial response to glucose. Segments of muscle-free jejunal mucosa were mounted in Ussing chambers to measure concentration-dependent changes in I_{sc} in response to glucose in *A. suum*-infected pigs after continuous daily feeding with *Bb12*. Values are means \pm SE for repeated experiments, *, $P < 0.05$ vs control pigs; Φ, $P < 0.05$ vs C/C-*A. suum*-infected pigs.

expression in liver between *Bb12* and placebo-treated pigs were compared at 17 days p.i. (Table 1). There was a 2.9-fold reduction in *MRC1*, a pattern recognition receptor, a 5.7-fold reduction in *IL25*, a 9.6-fold reduction in *STAT6*, a 1.8-fold reduction in *IL4*, and a 2.2-fold reduction in *IL1B*. No major change in gene expression was detected in the MLN of pigs from the various treatment groups (data not shown).

Antibody titers to *A. suum* and *Bb12* antigens

Parasite antigen-specific antibody responses in the serum and intestinal ileal fluid of *A. suum*-infected and *Bb12*-treated pigs were measured 21 days p.i. to determine changes in acquired immunity. Infection with *A. suum* significantly ($P > 0.05$) increased serum IgG1, and IgM anti-*Ascaris* L3/L4 antibodies compared to non-infected controls in both *Bb12* and placebo treated pigs ($p < 0.05$), while the levels of IgA anti-*Ascaris* L3/L4 antibodies were increased in *A. suum*-infected pigs treated with *Bb12* (T/T infected) compared to *A. suum*-infected pigs given placebo (C/C-infected) (Figure 7). In addition, there was a significant increase in IgG1 and IgG2 anti-*Ascaris* L3/L4 antibodies ($P < 0.05$) in the ileum fluid of *A. suum*-infected pigs treated with *Bb12* (T/T-infected) compared to the other groups. (Figure 8). IgM and IgA anti-*Ascaris* L3/L4 antibodies in the ileum fluid were not significantly affected by feeding *Bb12* (Figure 8).

Histological and morphometric analysis

Morphometric measurements were taken from sections of the jejunum of pigs 21 days p.i. to evaluate inflammation and cellular infiltration. There was no significant difference in the average villus height and crypt depth from five representative fields among the treatment groups (data not shown). There was a significant increase, however, in the number of eosinophils in *A. suum*-infected pigs fed the placebo (6.2 ± 1.6) compared to non-infected control pigs fed the placebo (1.6 ± 0.3) that was inhibited in infected pigs fed *Bb12* (2.5 ± 0.3 ; $p < 0.05$) (Table 2). Goblet cell numbers were not significantly changed, and mast cells were not detected.

4. Discussion

Clinical studies suggest that some probiotic bacteria can promote health and prevent disease;^{1,8,21,22} however the mechanisms underlying these beneficial effects are not well understood. In this study, the *in vivo* effect of *Bifidobacterium animalis subspecies lactis* (*Bb12*) on intestinal function and immunity against a parasitic nematode was evaluated. *Ascaris suum* is a persistent and common problem in swine raised worldwide, and the related species in humans, *A. lumbricoides* (large roundworm) infects an estimated 804 million people.²³ Although infections are common in countries with poor sanitation, ascariasis exhibit a cosmopolitan distribution with sporadic cases also described in developed countries²⁴ where pigs can be a source of infection.²⁵ Examination of the immunological and physiological responses to intestinal helminths also has been used to study local and systemic allergic disease.^{26,27}

The analysis of muscle-free segments of jejunum mucosa from *Bb12*-treated pigs showed no change in mucosal resistance or in net Cl^- ion flux in response to PGE₂, histamine, 5-hydroxytryptamine (5-HT), acetylcholine, and glucose compared to placebo-treated pigs indicating that the intestinal epithelium is functionally quiescent in pigs fed *Bb12*. Likewise, mucosal resistance, and secretion in response to PGE₂, remained unchanged in *A. suum*-infected pigs at 21 days p.i., but the secretory response to histamine and 5-HT were significantly increased. The enhanced mucosal responsiveness to these secretagogues is consistent with the mucosal mast cell hyperplasia that follows infection with *A. suum in vivo*,²⁸ and the




Figure 6. Gene expression in jejunum. Sections of jejunum from the small intestine of *A. suum*-infected pigs were collected 21 days p.i. All samples taken were processed and stored at -70°C . RNA and cDNA were prepared from each sample and expression of the indicated genes was analyzed using quantitative real-time PCR. Fluorescence signals measured during amplification were processed after amplification and were considered positive if the fluorescence intensity was 20-fold greater than the standard deviation of the baseline fluorescence. This level was the C_t value. Gene expression was normalized to a constant amount of RNA and cDNA amplified relative to the housekeeping gene LBP32. A statistical analysis was performed by using Statview 5.0 for Macintosh. Color-coded squares denote fold changes in gene expression; columns represent from left to right *A. suum*-infected pigs vs control pigs; *Bb12*-treated pigs vs control pigs; and *A. suum*-infected and *Bb12*-treated pigs vs control pigs, respectively. Statistical significance is indicated by A ($P \leq 0.05$) and B ($P < 0.1$).

functional changes and parasite antigen-induced release of histamine from mast cells isolated from the intestine of *A. suum*-infected pigs.²⁹ In the current study, however, a significant increase in mast cell numbers was not found by histological examination of the jejunum of *A. suum*-infected pigs. Jejunal tissues were fixed in buffered-formalin with the specific objective to evaluate potential morphometric changes due to exposure to *Bb12* or the interaction with *A. suum* infection. Metachromatic staining for pig mast cells, however, is facilitated by acidic fixation in Carnoy's and low pH staining with toluidine blue to preserve intracytoplasmic granule structure, which was not used in this study. In addition, young confinement-reared pigs have few detectable mast cells in the intestines compared to pigs raised on dirt or after chronic exposure to parasitic infection.²⁸

Nevertheless, the increase in basal I_{sc} in intestinal mucosa from *A. suum*-infected pigs in response to histamine *in vitro* is comparable to mast cell-dependent increases in fluid in the intestinal lumen that facilitate

Table 1. Type2-associated gene expression in liver of *A. suum*-infected pigs.

	Placebo	Bb12	Fold change relative to Placebo treatment
<i>MRC1</i>	6.21 ± 0.34 ^{1a}	7.72 ± 0.37 ^b	-2.9
<i>GATA3</i>	8.70 ± 0.18	8.96 ± 0.18	0.8
<i>IL25</i>	11.29 ± 0.36 ^a	13.81 ± 0.48 ^b	-5.7
<i>FCER1A</i>	6.67 ± 0.24	6.69 ± 0.24	0.9
<i>IL13</i>	13.36 ± 0.54	13.02 ± 0.37	1.3
<i>STAT6</i>	4.97 ± 0.32 ^a	8.23 ± 0.80 ^b	-9.6
<i>CCL26</i>	4.08 ± 0.88	2.77 ± 0.53	2.5
<i>IL4</i>	12.89 ± 0.24 ^a	13.75 ± 0.22 ^b	-0.5
<i>IL1B</i>	10.23 ± 0.30 ^a	11.38 ± 0.23 ^b	-2.2

¹Data represent the mean ± SE of ΔCt for associated Th2 signature genes. Means with different superscript letters are different with $p < 0.05$.




Figure 7. Anti-*Ascaris* L3/L4 antibodies in sera of pigs 21 days post inoculation (p.i.) with infective *A. suum* eggs. Immunolon plates were coated with *A. suum* L3/L4 antigen extract. OD₄₅₀ readings are means \pm SE. Different letters denote differences among treatments after ANOVA ($p < 0.05$) in (A) IgM, (B) IgG1, (C) IgG2, and (D) IgA.

worm expulsion during the period of self-cure in mice,³⁰ and may be a more sensitive indicator of functional mast cell activity in the pig intestine.²⁹ Concomitant treatment of *A. suum*-infected pigs with *Bb12* attenuated the hyper-secretory response to histamine (Figure 4) and the reduced sodium (Na)-linked glucose transport that contributes to parasite-induced edema in the intestinal lumen (Figure 5).³¹ These changes suggest that *Bb12* can modulate intestinal function without affecting host protection since parasite clearance from the proximal to distal small intestine was not significantly changed.

It is generally accepted that nematodes like *A. suum* are immunogenic and several studies have demonstrated high serum levels of *A. suum* antigen-specific antibodies after infection.³²⁻³⁴ In this study, there was a significant parasite-induced increase in serum IgM and IgG1 anti-*Ascaris* L3/L4 antibodies at 21 days p.i. that was not affected by feeding *Bb12*, while *Bb12* slightly enhanced IgA anti-*Ascaris* L3/L4 antibodies. The IgG1 and IgG2 anti-*Ascaris* L3/L4 antibody responses detected in the ileal fluid of *A. suum*-infected pigs were marginally but significantly

increased in pigs fed *Bb12*. Probiotics have been shown to enhance humoral immunity to viral infection^{35,36} and the capacity to increase immune responses to vaccine antigens.^{37,38} Specific antibody responses to *Bb12* antigen were observed only in ileal fluid of *Bb12*-treated pigs infected with *A. suum* (data not shown), suggesting a synergism that may be due to the enhanced polyclonal expansion of B cells commonly observed during parasitic infection or effects on antigen access and processing in the intestinal mucosa.

Changes in gene expression in the intestinal mucosa observed after infection with *A. suum* were characteristic of a type-2 cytokine response with significant up-regulation of *IL9*, *IL13*, mast cell-associated activation markers such as *FCER1A* and *TPSAB1*, and goblet cell-specific *RETNLB* ($P < 0.05$) (Figure 6). These changes reflect the stereotypical response to intestinal helminths observed in pigs infected with *A. suum*^{31,39} and in mice infected with several different gastrointestinal nematode parasites.⁴⁰ In the current study, all pigs born to *Bb12*-treated sows received oral *Bb12* from birth and had high numbers of copies of




Figure 8. Anti-*Ascaris* L3/L4 antibodies in ileum fluid of pigs 21 days post inoculation (p.i.) with infective *A. suum* eggs. Immunolon plates were coated with *A. suum* L3/L4 antigen. OD₄₅₀ readings are means \pm SE, different letters denote differences among treatments after ANOVA ($p < 0.05$) in (A) IgM, (B) IgG1, (C) IgG2, and (D) IgA.

the *Bb12 tuf* gene detected by PCR in the intestinal contents after six and nine weeks of continuous feeding; infection with *A. suum* did not affect *Bb12* copy number in the feces or proximal colon contents after infection. Treatment of pigs with *Bb12* induced a significant down-regulation of *IL3*, *TBX21*, and *RETNLB* expression in tissue from the proximal colon, and reduced *IL4* gene expression in jejunum (Figure 6); no changes were observed in the MLN of *Bb12*-treated pigs except for reduced *IGHE* gene expression (data not shown). These data indicated that *Bb12* alone exerts a relatively modest localized immune modulating effect on intestinal mucosa of treated pigs. In contrast, *Bb12*-treated pigs infected with *A. suum* showed

Table 2. Mean values for eosinophils and goblet cell distribution in jejunum lamina propria.

Treatment group	Goblet cell	Eosinophil
C/C control	13.6 \pm 1.2	1.6 \pm 0.3 ^b
C/C infected	17.9 \pm 1.5	6.2 \pm 1.6 ^a
T/T control	14.6 \pm 1.8	2.6 \pm 0.4 ^b
T/T infected	15.7 \pm 1.4	2.5 \pm 0.3 ^b

Treatment groups: C/C (*Ascaris* infected), T/T control, and T/T (*Ascaris* infected) are compared to C/C control. Statistical significance is indicated by^a ($P \leq 0.05$).

a significant alteration in the expression of several genes associated with a type-2 response to *A. suum* (Figure 6). Up-regulation of *IL13* was maintained with a concomitant down-regulation of the *IL13RA1* chain that is the functional component of the IL-4 receptor complex for IL-13 binding. This finding is consistent with that reported in pigs infected with *Trichuris suis*⁴¹ but suggests that feeding *Bb12* can modulate IL-13 signaling capacity. The expression of *IL25* and *RETNLB*, two genes associated with the regulation of type 2 cytokine-dependent immunity against parasites, were significantly up-regulated ($p < 0.05$) in the jejunum of *A. suum*-infected pigs fed *Bb12*. *RETNLB*, characteristically expressed by goblet cells in the intestine, has been associated with protection against helminths with maximal secretion of RELM beta protein correlated with enhanced Th2 cytokine expression and worm expulsion.⁴²⁻⁴⁵ *IL-25* also has been identified as a critical mediator of type 2 immunity since it is required for regulation of inflammation in gastrointestinal tract.^{43,46,47} There also was a significant decrease in *SOCS3* expression ($P < 0.05$), a major negative feedback regulator of signal transducer, that affects production of the immune regulatory cytokines

TGF β 1 and IL-10 through modulation of STAT3⁴⁸ and regulation of IL-17 secreting cells.⁴⁹ A significant down-regulation in *IL10* gene expression in the jejunum of *A. suum*-infected pigs fed *Bb12* indicated a reduced IL-10 dependent response to infection with *A. suum*.⁵⁰ It should be noted, however, that changes in these regulatory genes could represent a *Bb12*-induced palliative mechanism that reduced local *A. suum* induced-eosinophilia in the intestine with no significant effect on parasite expulsion (Table 2). Additional studies that include repetitive and longer exposure to infection, and the effects on memory responses and associated pathology, would be required to test this hypothesis.

Reducing IFN- γ -dependent responses to non-pathogenic bacteria while mounting an appropriate Th1-mediated response to pathogenic bacteria is key to maintenance of physiological homeostasis.⁵¹ The down-regulation of IFN γ and *IL10* mRNA expression in *Bb12*-treated pigs infected with *A. suum* could represent a beneficial effect of probiotics on intestinal mucosa perturbed by nematode infection. Certain probiotic bacteria reduce pro-inflammatory IFN- γ production independent of *IL10*.^{51,52} The significant down-regulation of *TLR9* in the jejunum of *A. suum*-infected pigs exposed to *Bb12* may also limit bacterial-induced inflammation of the intestinal mucosa.⁵³

Protease-activated receptor-1 (PAR-1, *F2R*) expression is activated by proteases in a variety of tissues including the gastrointestinal tract.⁵⁴ Helminth-induced activation of PAR-1 is dependent on IL-13-activated STAT6 signaling pathway independent of IL4.⁵⁵ Activation of PAR-1 induces Cl⁻ secretion by intestinal epithelial cells through cyclooxygenase-dependent pathways.^{56,57} Although the mechanism is unknown, immune regulation of PAR-1 and COX2 activity or expression in intestinal mucosa represents novel therapeutic targets given that many reactive allergens and helminths express protease moieties that enhance PAR-1 activation. The significant down-regulation observed in gene expression for both *-F2R* (5-fold) and *PTGS2* (2-fold) in pigs infected with *A. suum* and fed *Bb12* indicates a potentially novel effect of probiotic treatment on intestinal inflammation associated with barrier dysfunction,^{57,58} such as is observed in inflammatory bowel disease and celiac disease.

Cytokines directly affect epithelial functions including barrier stability^{59,61} and electrolyte transport

across the intestinal mucosa.^{6,30,62} Various stimuli including cytokines, allergens, and bacterial products enhance mucosal permeability by affecting tight junction (TJ) integrity.^{59,63} Infection of pigs with *A. suum* or treatment with *Bb12* had no effect on epithelial barrier function (resistance) or Cl⁻ secretory responses to acetylcholine and prostaglandin E2. *Bb12* treatment, however, abrogated the histamine-induced Cl⁻ secretory response to *A. suum*. In addition, infection with *A. suum* or treatment with *Bb12* did not change expression for the Cl⁻ channel gene *CLCA1* and paracellular permeability genes *TJP2*, *TJP3*, and *OCN*. There was, however, a 2-fold down-regulation of *TJP1* in the jejunal mucosa of *Bb12*-treated pigs infected with *A. suum*.

Glucose is the single most abundant actively transported nutrient in human diets. It is transported across the apical or luminal surface via Na-linked glucose transporter SGLT1 (*SLC5A1*), and the basolateral membrane through the facilitated glucose exchanger GLUT2 (*SLC2A2*).⁶⁴ Trans-epithelial ion transport results in the generation of a negative potential difference (PD) due the active absorption of Na⁺ ions. The current that is necessary to bring the PD continuously to zero voltage is called the short circuit current (I_{sc}) and is the real time measurement of the net electrogenic transport across an epithelium.⁶⁵ Pigs infected with *A. suum* and treated with *Bb12* had a reduction in I_{sc}, indicating a decreased Na-linked transport of glucose. Gene expression for the luminal surface transporter SGLT1 (*SLC5A1*) did not increase in these pigs suggesting that other mechanisms may be responsible for the reversal of the normal intestinal response to parasite infection. In rodent models of parasite infection, epithelial glucose absorption has been shown to be regulated by macrophages without affecting its expression in the intestine.⁶⁶

While changes in gene expression related to both pro- and anti-inflammatory pathways were relatively minor in pigs treated with *Bb12*, the effects of feeding *Bb12* were more pronounced in pigs following infection with *A. suum*. This pattern is similar to that observed during infection with *Salmonella* or *E. coli* in animals treated with probiotics^{67,13,14} suggesting that probiotic efficacy is best observed in tissues exposed to an inflammatory stimulus.

We have demonstrated that *Bb12* regulates an efficient type-2-dependent response to parasite infection in the intestine by reducing local

intestinal eosinophilic infiltration, the histamine-induced Cl^- secretory response, and blocking the inhibitory effects of infection on glucose absorption, while enhancing acquired antibody responses to infection. These data suggest that feeding *Bb12* can ameliorate dysregulated type-2 diseases such as allergy and chronic inflammation, and can enhance systemic and local antibody production to certain infections and, by extension, to appropriate immunization strategies.

Material and methods

Animals: All pigs used in these studies were cross-bred Yorkshire X Poland-China pigs (males and females) born and maintained at the Beltsville Agricultural Research Center swine facility under management conditions approved by the Beltsville Area Animal Care and Use Committee. Six sows were bred by artificial insemination after hormonal synchronization. Pregnant sows were treated with oral administration of either *Bb12* probiotic or placebo (maltodextrin vehicle without *Bb12*) starting the last third of gestation, during nursing, and until weaning of the piglets at three weeks after birth. Three sows received a daily oral dose of 2.2 g of freeze-dried *Bb12* (10 billion CFU/g) provided by Christian Hansen, Denmark, as a 100% pure lyophilized product dissolved in 10 mL of sterile PBS, and three additional sows received a daily oral dose of placebo only. Both products (placebo and probiotic) were microbiologically tested throughout the experiment as previously described.²⁰ Piglets born from *Bb12*-treated sows also were treated with a daily probiotic dose of 1.1 g (10 billion CFU/g) of *Bb12* starting shortly after birth until approximately 2.5 months of age (Treated/Treated = T/T group). Piglets born from placebo-treated sows received a daily dose of 1.1 g of placebo preparation starting at birth until the end of the experiment at approximately 2.5 months of age (Control/Control = C/C group). All piglets were weaned at week three after birth and allocated to individual pens with feed and water *ad libitum*. To prevent cross-contamination among treatment groups ($n = 6\text{--}8/\text{group}$), T/T and C/C pigs were housed in pens at opposite sides of the barn.

In a second study, four sows were also treated with oral administration of either *Bb12* probiotic ($n = 2$) or

placebo (maltodextrin vehicle without *Bb12*, $n = 2$) as in the first study. Similarly, seven pigs derived from each treatment group were allocated to individual pens to continue the dietary treatment for 2.5 months before collection of samples.

Inoculation with *Ascaris suum*

The acquisition and preparation of infective *A. suum* eggs, oral inoculation, and management of pigs have been described.²⁸ In the first experiment, eight piglets from the T/T group and six piglets from the C/C group were inoculated with an oral dose of 2.5×10^4 *A. suum* eggs, and euthanized at day 21 post inoculation (p.i.). The remaining six animals of the T/T and C/C treatment groups were non-infected controls. Infected pigs were segregated on solid floors from non-infected (control) pigs by a center island that restricted water and particle flow between the opposite ends of the barn. “White spot” liver lesions, an indicator of active migration of *A. suum* larvae through the liver, were detected in inoculated pigs, but not control non-infected pigs at necropsy. This observation indicated that none of the control pigs were inadvertently infected.

In a second experiment, pigs born from four sows were split into the *Bb12* T/T group ($n = 7$) and placebo C/C group ($n = 7$) before oral inoculation with 2.5×10^4 *A. suum* eggs, and euthanized 17 days p.i. to collect *A. suum* L4 from the small intestine prior to natural expulsion.³²

Parasite counts

Parasite expulsion is indicated by the displacement of L4 from the proximal to the distal small intestine between 17 and 21 days p.i., and six equivalent sections of the small intestine of each pig were examined for L4.⁶⁸ Protective immunity to *A. suum* was determined by comparing the number and location of L4 in the intestines of *Bb12*-treated versus placebo-treated pigs at 21 days p.i., for pigs in the first experimental group, and 17 days p.i. for pigs in the second experimental group.

Quantitative detection of *Bb12* in fecal samples and intestinal contents

A 5 g fecal sample was collected in a sterile 50mL conical tube at weaning, three weeks after weaning (pre-

infection) and 17 or 21 days p.i. DNA from the fecal samples or proximal colon contents collected at necropsy was isolated using the QIAamp DNA Stool mini kit (Qiagen, Valencia, CA) as previously described.²⁰ The abundance of *Bb12* in treated-pigs was determined using the primer-probe set against the *Bifidobacterium animalis subspecies lactis tuf* gene.²⁰

Relative mRNA host gene expression by quantitative real time PCR

Tissue sections from liver, jejunum, proximal colon, and mesenteric lymph nodes (MLN) collected at necropsy were frozen immediately in liquid nitrogen and stored at -70°C until RNA extraction. Tissue RNA was extracted after homogenization in Trizol reagent (Invitrogen, Gaithersburg, MD), and quantitative real time PCR was performed on cDNA synthesized from each sample using 10 μg of total RNA as previously described.⁶⁹ Sequences for all probes and primers selected for real time PCR assays were obtained from the Porcine Translational Research Database (<http://www.ars.usda.gov/Services/docs.htm?docid=6065>).⁷⁰

Fluorescence signals were processed after amplification and were considered positive if the fluorescence intensity was greater than 20-fold or more than the standard deviation of the baseline fluorescence. Gene expression was normalized based upon a constant amount of RNA and cDNA amplified.^{31,71,72} Relative quantification of target gene expression was evaluated by comparing C_t values from cDNA processed from non-infected pigs and *A. suum*-infected pigs at 17 or 21 days p.i. after normalization with the housekeeping gene RPL32. Up- or down-regulation in gene expression is denoted by fold changes in C_t values.

Measurement of epithelial cell function ex vivo

Four segments of mucosa (0.126 cm^2) were stripped of muscle and mounted in Ussing chambers exposed to 10 mL of Krebs's buffer.³¹ Briefly, agar salt bridges and electrodes were used to measure potential difference. The tissues were short-circuited at 1V (DVC World Precision Instruments, Sarasota, FL) every 50 s, and the short circuit current (I_{sc}) continuously monitored. In addition, every 50 s the clamp voltage was adjusted to 1 V for 10 s to allow calculation of tissue resistance using Ohm's law. Following a 15min equilibration period, basal I_{sc} representing the net Cl^- ion flux before stimulation (baseline), and tissue resistance

were measured. After a second 15 min period, concentration-dependent changes in I_{sc} were determined in response to the cumulative addition of 5-hydroxytryptamine (5-HT), acetylcholine (ACH), histamine, or PGE_2 to the serosal side of the intestine. Following re-equilibration, concentration dependent changes in I_{sc} were measured in response to the cumulative addition of glucose to the mucosal side. All responses from treated-tissue segments from control and *A. suum* infected-pigs were averaged to yield a mean response per treatment group in the first experiment. Mucosal segments from jejunum also were collected in the second experiment for measurement of similar physiological responses.

Detection of parasite antigen-specific IgA, IgG, and IgM antibodies

Specific antibodies against *A. suum* were measured in the first experiment only. ELISA plates (Immunolon, Nunc, Thermo Fisher Scientific, Waltham, MA) were coated with 100 μL of 5 $\mu\text{g}/\text{mL}$ of *A. suum* 3rd to 4th stage larvae (L3/L4) extract⁷³ or 0.1 μg of lyophilized *Bb12* in coating buffer (Sodium Carbonate buffer, pH 9.5). After an overnight incubation at 4°C , plates were washed six times (0.05% Tween 20 in 1X-PBS) and blocked with 0.05% Tween 20, 0.5% BSA in PBS for 30 minutes. Plates were washed and used for testing 100 μL of serum diluted at 1:3,000 and 1:6,000 (0.05% Tween 20 in PBS) or ileum fluid (contents obtained from the terminal 60 cm of pig intestine were centrifuged at 4C and 800 X g for 10 minutes to separate clear fluid from particulates). Test samples were run in duplicates and incubated for two hr at room temperature. After six washes, 100 μL of HRP-conjugated porcine anti-IgM, anti-IgA, anti-IgG1 or anti-IgG2 (Serotec, Raleigh, NC) were added at a 1:10,000 dilution and incubated for one hr. After a final wash, 100 μL of TMB-One substrate solution (Promega, Madison, WI) was added. Total anti-L3/L4 or anti-*Bb12*-specific antibody isotypes were determined after reading plates with an optical density (OD) at 450nm after 20 minutes. Reaction was stopped by addition of 1M HCl solution.

Histological and morphometric analysis of jejunum

Cross-sections of jejunum from the first experiment were fixed in 10% neutral buffered formalin and submitted to the University of Minnesota Diagnostic

Laboratory (St. Paul, MN) for histological analysis. Routine paraffin-embedded tissue blocks were sectioned at 4 μm and stained with hematoxylin and eosin (H&E). Villus height and crypt depth were measured by an observer blinded to treatment. The mean length of 15 well-oriented and representative villi and crypts were measured respectively from each pig. In addition, toluidine blue staining was performed for characterization of cellular components in the intestinal sections. Goblet cells and eosinophils were counted and mean values reported after evaluation of five independent fields under 40X magnification. Measurements were taken using an Olympus BX40 microscope (Olympus Optical Co., LTD, Japan) equipped with a Spot, InSight Color Model 3.20 digital camera and imaging software (Diagnostic Instruments Inc., Sterling Heights, MI).

Processing of data and statistical analysis

Bb12 in feces and the intestinal contents collected at necropsy were determined by quantitative detection of *Bb12-tuf*-gene copies. Data were log-transformed and C_t values compared among dietary treatment groups. Contrast statements were run to compare the effect of parasite infection among treatment groups. Data were transformed to log base to represent bacterial copy numbers per gram (cpg) of *Bb12* using the *tuf* gene as the bacterial marker (mean \pm standard error). Statistical results were noted for mean values from each treatment group where any non-identical letters^(abc) indicated significant differences at $P \leq 0.05$. The effect of infection with *A. suum* on tissue mRNA gene expression (C_t values) and cell numbers were evaluated using one-way ANOVA analysis and comparing values obtained in samples from *A. suum*-infected and non-infected pigs. Fisher's LSD post-hoc test was applied to access differences between treatment groups at 17 and 21 days p.i. $P \leq 0.05$ was considered statistically significant for all analyses (Statview 5.0 for Macintosh Abacus Concepts, Berkeley, CA). Differences in mucosal resistance were assessed for both experiments using a one-way ANOVA and concentration-dependent changes in I_{sc} or smooth muscle contractility were assessed by multiple ANOVA. All ANOVA tests were followed by t-tests to evaluate differences between means.

Conflict of interest statement

The authors have no conflicts of interest to disclose.

Financial disclosure statement

This work was funded by USDA project plan 8042-31000-107-00D. The authors have no financial relationships relevant to this article to disclose.

Acknowledgments

The authors thank Alyssa Kendall from Diet, Genomics, and Immunology Laboratory for assistance in running some samples for real-time PCR analyses, and Dr. Josh Parker from University of Minnesota for histopathological processing and analysis of pig intestinal sections.

Funding

USDA-ARS 8042-31000-107-00D.

Disclaimer

The views expressed in this article are those of the authors and do not reflect the official policy or position of the United States Department of Agriculture, Department of Defense, or the U.S. government. Title 17 U.S.C. 105 provides that "copyright protection under this title is not available for any work of the United States Government." Title 17 U.S.C. 101 defines a United States government work as "a work prepared by a military service member or employee of the United States government as part of that person's official duties." This work was prepared as part of the official duties of Drs.

Solano-Aguilar, Madden, Dawson, Urban Jr., Lakshman and Mrs. Beshah.

"Mention of trade names or commercial products in this publication is solely for the purpose of providing specific information and does not imply recommendation or endorsement by the USDA."

"USDA is an equal opportunity provider and employer"

References

1. Limdi JK, O'Neill C, McLaughlin J. Do probiotics have a therapeutic role in gastroenterology?. *World J Gastroenterol.* 2006;12:5447–57.
2. Kunzelmann K, Mall M. Electrolyte transport in the mammalian colon: mechanisms and implications for disease. *Physiol Rev.* 2002;82:245–89. doi:10.1152/physrev.00026.2001.
3. France MM, Turner JR. The mucosal barrier at a glance. *J Cell Sci.* 2017;130:307–14. doi:10.1242/jcs.193482.
4. Bischoff SC, Barbara G, Buurman W, Ockhuizen T, Schulzke JD, Serino M, Tilg H, Watson A, Wells JM. Intestinal permeability—a new target for disease prevention and

- therapy. *BMC Gastroenterol.* **2014**;14:189. doi:10.1186/s12876-014-0189-7.
5. Capaldo CT, Powell DN, Kalman D. Layered defense: how mucus and tight junctions seal the intestinal barrier. *J Mol Med (Berl).* **2017**;95:927–34. doi:10.1007/s00109-017-1557-x.
 6. Madden KB, Whitman L, Sullivan C, Gause WC, Urban JF Jr, Katona IM, Finkelman FD, Shea-Donohue T. Role of STAT6 and mast cells in IL-4- and IL-13-induced alterations in murine intestinal epithelial cell function. *J Immunol.* **2002**;169:4417–22.
 7. Dhama K, et al. Probiotics in Curing Allergic and Inflammatory Conditions – Research progress and Futuristic vision. *Recent Pat Inflamm Allergy Drug Discov.* **2017**;10:105–18. doi:10.2174/1872213X10666161226162229.
 8. Shi HN, Walker A. Bacterial colonization and the development of intestinal defences. *Can J Gastroenterol.* **2004**;18:493–500.
 9. Rondanelli M, et al. Using probiotics in clinical practice: Where are we now? A review of existing meta-analyses. *Gut Microbes.* **2017**;8:521–43. doi:10.1080/19490976.2017.1345414.
 10. Hayes SR, Vargas AJ. Probiotics for the prevention of Pediatric Antibiotic-Associated Diarrhea. *Explore (NY).* **2016**;12:463–6. doi:10.1016/j.explore.2016.08.015.
 11. Tojo R, Suárez A, Clemente MG, de los Reyes-Gavilán CG, Margolles A, Gueimonde M, Ruas-Madiedo P. Intestinal microbiota in health and disease: role of bifidobacteria in gut homeostasis. *World J Gastroenterol.* **2014**;20:15163–76. doi:10.3748/wjg.v20.i41.15163.
 12. Hemarajata P, Versalovic J. Effects of probiotics on gut microbiota: mechanisms of intestinal immunomodulation and neuromodulation. *Therap Adv Gastroenterol.* **2013**;6:39–51. doi:10.1177/1756283X12459294.
 13. Roselli M, Finamore A, Britti MS, Mengheri E. Probiotic bacteria *Bifidobacterium animalis* MB5 and *Lactobacillus rhamnosus* GG protect intestinal Caco-2 cells from the inflammation-associated response induced by enterotoxigenic *Escherichia coli* K88. *Br J Nutr.* **2006**;95:1177–84.
 14. O'Hara AM, et al. Functional modulation of human intestinal epithelial cell responses by *Bifidobacterium infantis* and *Lactobacillus salivarius*. *Immunology.* **2006**;118:202–15. doi:10.1111/j.1365-2567.2006.02358.x.
 15. Takahashi N, et al. Immunostimulatory oligodeoxynucleotide from *Bifidobacterium longum* suppresses Th2 immune responses in a murine model. *Clin Exp Immunol.* **2006**;145:130–8. doi:10.1111/j.1365-2249.2006.03111.x.
 16. Takahashi N, Kitazawa H, Iwabuchi N, Xiao JZ, Miyaji K, Iwatsuki K, Saito T. Oral administration of an immunostimulatory DNA sequence from *Bifidobacterium longum* improves Th1/Th2 balance in a murine model. *Biosci Biotechnol Biochem.* **2006**;70:2013–7.
 17. Saxelin M, Tynkynen S, Mattila-Sandholm T, de Vos WM. Probiotic and other functional microbes: from markets to mechanisms. *Curr Opin Biotechnol.* **2005**;16:204–11. doi:10.1016/j.copbio.2005.02.003.
 18. Saavedra JM, Abi-Hanna A, Moore N, Yolken RH. Long-term consumption of infant formulas containing live probiotic bacteria: tolerance and safety. *Am J Clin Nutr.* **2004**;79:261–7.
 19. Jang S, et al. Flavanol-Rich Cocoa Powder interacts with *Lactobacillus rhamnosus* LGG to alter the Antibody Response to infection with the Parasitic Nematode *Ascaris suum*. *Nutrients.* **2017**;9(10):1113. doi:10.3390/nu9101113.
 20. Solano-Aguilar G, et al. Detection of *Bifidobacterium animalis subsp. lactis* (Bb12) in the intestine after feeding of sows and their piglets. *Appl Environ Microbiol.* **2008**;74:6338–47. doi:10.1128/AEM.00309-08.
 21. Karimi O, Pena AS. Probiotics: Isolated bacteria strain or mixtures of different strains? Two different approaches in the use of probiotics as therapeutics. *Drugs Today (Barc).* **2003**;39:565–97.
 22. Yan F, Polk DB. Commensal bacteria in the gut: learning who our friends are. *Curr Opin Gastroenterol.* **2004**;20:565–71.
 23. Jourdan PM, Lambertson PHL, Fenwick A, Addiss DG. Soil-transmitted helminth infections. *Lancet.* **2018**;391:252–265. doi:10.1016/S0140-6736(17)31930-X.
 24. Betson M, Nejsun P, Bendall RP, Deb RM, Stothard JR. Molecular epidemiology of ascariasis: a global perspective on the transmission dynamics of *Ascaris* in people and pigs. *J Infect Dis.* **2014**;210:932–41. doi:10.1093/infdis/jiu193.
 25. Miller LA, Colby K, Manning SE, Hoenig D, McEvoy E, Montgomery S, Mathison B, de Almeida M, Bishop H, Dasilva A. Ascariasis in humans and pigs on small-scale farms, Maine, USA, 2010–2013. *Emerg Infect Dis.* **2015**;21:332–4. doi:10.3201/eid2102.140048.
 26. Acevedo N, Mohr J, Zakzuk J, Samonig M, Briza P, Erler A, Pomés A, Huber CG, Ferreira F, Caraballo L. Proteomic and immunochemical characterization of glutathione transferase as a new allergen of the nematode *Ascaris lumbricoides*. *PLoS One.* **2013**;8:e78353. doi:10.1371/journal.pone.0078353.
 27. Caraballo L, Zakzuk J, Lee BW, Acevedo N, Soh JY, Sánchez-Borges M, Hossny E, García E, Rosario N, Anso-tegui I. Particularities of allergy in the Tropics. *World Allergy Organ J.* **2016**;9:20. doi:10.1186/s40413-016-0110-7.
 28. Urban JF, Jr., Alizadeh H, Romanowski RD. *Ascaris suum*: development of intestinal immunity to infective second-stage larvae in swine. *Exp Parasitol.* **1988**;66:66–77.
 29. Ashraf M, Urban JF, Jr., Lee TD, Lee CM. Characterization of isolated porcine intestinal mucosal mast cells following infection with *Ascaris suum*. *Vet Parasitol.* **1988**;29:143–58.
 30. Shea-Donohue T, et al. The role of IL-4 in *Heligmosomoides polygyrus*-induced alterations in murine intestinal epithelial cell function. *J Immunol.* **2001**;167:2234–9.
 31. Dawson HD, et al. Localized multigene expression patterns support an evolving Th1/Th2-like paradigm in response to infections with *Toxoplasma gondii* and *Ascaris*

- suum*. Infect Immun. 2005;73:1116–28. doi:10.1128/IAI.73.2.1116-1128.2005.
32. Miquel N, Roepstorff A, Bailey M, Eriksen L. Host immune reactions and worm kinetics during the expulsion of *Ascaris suum* in pigs. Parasite Immunol. 2005;27:79–88. doi:10.1111/j.1365-3024.2005.00752.x.
33. Frontera E, Roepstorff A, Serrano FJ, Gázquez A, Reina D, Navarrete I. Presence of immunoglobulins and antigens in serum, lung and small intestine in *Ascaris suum* infected and immunised pigs. Vet Parasitol. 2004;119:59–71. doi:10.1016/j.vetpar.2003.09.022.
34. Eriksen L, Bogh HO, Loftager M, Lind P. Comparative studies of experimental oral inoculation of pigs with *Ascaris suum* eggs or third stage larvae. J Vet Med B Infect Dis Vet Public Health. 2004;51:185–90. doi:10.1111/j.1439-0450.2004.00752.x.
35. Yasui H, Kiyoshima J, Hori T, Shida K. Protection against influenza virus infection of mice fed *Bifidobacterium breve* YIT4064. Clin Diagn Lab Immunol. 1999;6:186–92.
36. Qiao H, et al. Immune responses in rhesus rotavirus-challenged BALB/c mice treated with bifidobacteria and prebiotic supplements. Pediatr Res. 2002;51:750–5. doi:10.1203/00006450-200206000-00015.
37. Rautava S, Arvilommi H, Isolauri E. Specific probiotics in enhancing maturation of IgA responses in formula-fed infants. Pediatr Res. 2006;60:221–4. doi:10.1203/01.pdr.0000228317.72933.db.
38. Schierack P, Filter M, Scharek L, Toelke C, Taras D, Tedin K, Haverson K, Lübke-Becker A, Wieler LH. *Bacillus cereus* var. *toyoi* enhanced systemic immune response in piglets. Vet Immunol Immunopathol. 2007;118:1–11. doi:10.1016/j.vetimm.2007.03.006.
39. Zarlenga DS, Dawson H, Kringel H, Solano-Aguilar G, Urban JF, Jr. Molecular cloning of the swine IL-4 receptor alpha and IL-13 receptor 1-chains: effects of experimental *Toxoplasma gondii*, *Ascaris suum* and *Trichuris suis* infections on tissue mRNA levels. Vet Immunol Immunopathol. 2004;101:223–34. doi:10.1016/j.vetimm.2004.05.003.
40. Shea-Donohue T, Urban JF, Jr. Gastrointestinal parasite and host interactions. Curr Opin Gastroenterol. 2004;20:3–9.
41. Kringel H, Iburg T, Dawson H, Aasted B, Roepstorff A. A time course study of immunological responses in *Trichuris suis* infected pigs demonstrates induction of a local type 2 response associated with worm burden. Int J Parasitol. 2006;36:915–24. doi:10.1016/j.ijpara.2006.04.008.
42. Artis D. New weapons in the war on worms: identification of putative mechanisms of immune-mediated expulsion of gastrointestinal nematodes. Int J Parasitol. 2006;36:723–33. doi:10.1016/j.ijpara.2006.02.011.
43. Owyang AM, et al. Interleukin 25 regulates type 2 cytokine-dependent immunity and limits chronic inflammation in the gastrointestinal tract. J Exp Med. 2006;203:843–9. doi:10.1084/jem.20051496.
44. Artis D, et al. RELMbeta/FIZZ2 is a goblet cell-specific immune-effector molecule in the gastrointestinal tract. Proc Natl Acad Sci U S A. 2004;101:13596–600. doi:10.1073/pnas.0404034101.
45. Hogan SP, et al. Resistin-like molecule beta regulates innate colonic function: barrier integrity and inflammation susceptibility. J Allergy Clin Immunol. 2006;118:257–68. doi:10.1016/j.jaci.2006.04.039.
46. Fallon PG, Ballantyne SJ, Mangan NE, Barlow JL, Dasvarma A, Hewett DR, McIlgorm A, Jolin HE, McKenzie AN. Identification of an interleukin (IL)-25-dependent cell population that provides IL-4, IL-5, and IL-13 at the onset of helminth expulsion. J Exp Med. 2006;203:1105–16. doi:10.1084/jem.20051615.
47. Cliffe LJ, Humphreys NE, Lane TE, Potten CS, Booth C, Grecnis RK. Accelerated intestinal epithelial cell turnover: a new mechanism of parasite expulsion. Science. 2005;308:1463–5. doi:10.1126/science.1108661.
48. Kinjyo I, Inoue H, Hamano S, Fukuyama S, Yoshimura T, Koga K, Takaki H, Himeno K, Takaesu G, Kobayashi T. Loss of SOCS3 in T helper cells resulted in reduced immune responses and hyperproduction of interleukin 10 and transforming growth factor-beta 1. J Exp Med. 2006;203:1021–31. doi:10.1084/jem.20052333.
49. Chen Z, Laurence A, Kanno Y, Pacher-Zavisin M, Zhu BM, Tato C, Yoshimura A, Hennighausen L, O’Shea JJ. Selective regulatory function of Socs3 in the formation of IL-17-secreting T cells. Proc Natl Acad Sci U S A. 2006;103:8137–42. doi:10.1073/pnas.0600666103.
50. Silva SR, Jacysyn JF, Macedo MS, Faquim-Mauro EL. Immunosuppressive components of *Ascaris suum* down-regulate expression of costimulatory molecules and function of antigen-presenting cells via an IL-10-mediated mechanism. Eur J Immunol. 2006;36:3227–37. doi:10.1002/eji.200636110.
51. Sheil B, MacSharry J, O’Callaghan L, O’Riordan A, Waters A, Morgan J, Collins JK, O’Mahony L, Shanahan F. Role of interleukin (IL-10) in probiotic-mediated immune modulation: an assessment in wild-type and IL-10 knockout mice. Clin Exp Immunol. 2006;144:273–80. doi:10.1111/j.1365-2249.2006.03051.x.
52. McCarthy J, et al. Double blind, placebo controlled trial of two probiotic strains in interleukin 10 knockout mice and mechanistic link with cytokine balance. Gut. 2003;52:975–80.
53. Rachmilewitz D, et al. Toll-like receptor 9 signaling mediates the anti-inflammatory effects of probiotics in murine experimental colitis. Gastroenterology. 2004;126:520–8.
54. Vergnolle N. Review article: proteinase-activated receptors – novel signals for gastrointestinal pathophysiology. Aliment Pharmacol Ther. 2000;14:257–66.
55. Zhao A, Morimoto M, Dawson H, Elfrey JE, Madden KB, Gause WC, Min B, Finkelman FD, Urban JF Jr, Shea-Donohue T. Immune regulation of protease-activated receptor-1 expression in murine small intestine during *Nippostrongylus brasiliensis* infection. J Immunol. 2005;175:2563–9.
56. Buresi MC, Buret AG, Hollenberg MD, MacNaughton WK. Activation of proteinase-activated receptor 1

- stimulates epithelial chloride secretion through a unique MAP kinase- and cyclo-oxygenase-dependent pathway. *FASEB J.* **2002**;16:1515–25. doi:10.1096/fj.02-0039com.
57. Resta-Lenert S, Barrett KE. Enteroinvasive bacteria alter barrier and transport properties of human intestinal epithelium: role of iNOS and COX-2. *Gastroenterology.* **2002**;122:1070–87.
 58. Zamuner SR, Warriar N, Buret AG, MacNaughton WK, Wallace JL. Cyclooxygenase 2 mediates post-inflammatory colonic secretory and barrier dysfunction. *Gut.* **2003**;52:1714–20.
 59. McDermott JR, et al. Mast cells disrupt epithelial barrier function during enteric nematode infection. *Proc Natl Acad Sci U S A.* **2003**;100:7761–6. doi:10.1073/pnas.1231488100.
 60. Ceponis PJ, Botelho F, Richards CD, McKay DM. Interleukins 4 and 13 increase intestinal epithelial permeability by a phosphatidylinositol 3-kinase pathway. Lack of evidence for STAT 6 involvement. *J Biol Chem.* **2000**;275:29132–7. doi:10.1074/jbc.M003516200.
 61. Youakim A, Ahdieh M. Interferon-gamma decreases barrier function in T84 cells by reducing ZO-1 levels and disrupting apical actin. *Am J Physiol.* **1999**;276:G1279–1288.
 62. Zhao A, McDermott J, Urban JF Jr, Gause W, Madden KB, Yeung KA, Morris SC, Finkelman FD, Shea-Donohue T. Dependence of IL-4, IL-13, and nematode-induced alterations in murine small intestinal smooth muscle contractility on Stat6 and enteric nerves. *J Immunol.* **2003**;171:948–54.
 63. Fasano A, Shea-Donohue T. Mechanisms of disease: the role of intestinal barrier function in the pathogenesis of gastrointestinal autoimmune diseases. *Nat Clin Pract Gastroenterol Hepatol.* **2005**;2:416–22. doi:10.1038/ncpgasthep0259.
 64. Turner JR, Cohen DE, Mrsny RJ, Madara JL. Noninvasive in vivo analysis of human small intestinal paracellular absorption: regulation by Na⁺-glucose cotransport. *Dig Dis Sci.* **2000**;45:2122–6.
 65. Seidler U, et al. Molecular mechanisms of disturbed electrolyte transport in intestinal inflammation. *Ann N Y Acad Sci.* **2006**;1072:262–75. doi:10.1196/annals.1326.024.
 66. Notari L, et al. Role of macrophages in the altered epithelial function during a type 2 immune response induced by enteric nematode infection. *PLoS One.* **2014**;9:e84763. doi:10.1371/journal.pone.0084763.
 67. Riedel CU, Foata F, Philippe D, Adolffson O, Eikmanns BJ, Blum S. Anti-inflammatory effects of bifidobacteria by inhibition of LPS-induced NF-kappaB activation. *World J Gastroenterol.* **2006**;12:3729–35.
 68. Morimoto M, et al. *Ascaris suum*: cDNA microarray analysis of 4th stage larvae (L4) during self-cure from the intestine. *Exp Parasitol.* **2003**;104:113–21.
 69. Solano Aguilar GI, et al. Cytokine and lymphocyte profiles in miniature swine after oral infection with *Toxoplasma gondii* oocysts. *Int J Parasitol.* **2001**;31:187–95.
 70. Dawson HD, Chen C, Gaynor B, Shao J, Urban JF, Jr. The porcine translational research database: a manually curated, genomics and proteomics-based research resource. *BMC Genomics.* **2017**;18:643. doi:10.1186/s12864-017-4009-7.
 71. Bustin SA. Quantification of mRNA using real-time reverse transcription PCR (RT-PCR): trends and problems. *J Mol Endocrinol.* **2002**;29:23–39.
 72. Dawson HD, Royae AR, Nishi S, Kuhar D, Schnitzlein WM, Zuckermann F, Urban J Jr, Lunney JK. Identification of key immune mediators regulating T helper 1 responses in swine. *Vet Immunol Immunopathol.* **2004**;100:105–11. doi:10.1016/j.vetimm.2004.03.006.
 73. Urban JF, Jr., Romanowski RD. *Ascaris suum*: protective immunity in pigs immunized with products from eggs and larvae. *Exp Parasitol.* **1985**;60:245–54.